This view is supported by the observation that TGFβ signaling was reduced in subcutaneous mammary adenocarcinoma and in PDAC metastatic liver lesions after repeated administration of 5a-HSA to tumor-bearing mice. The gene discussed is TGFB1; the disease is breast adenocarcinoma.